🚀 VC round data is live in beta, check it out!
AN2 Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for AN2 Therapeutics and similar public comparables like Zomedica, Sangamo Therapeutics, Nykode Therapeutics, ProMIS Neurosciences and more.
AN2 Therapeutics Overview
About AN2 Therapeutics
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
Founded
2017
HQ
Employees
22
Website
Sectors
Financials (FY)
EV
$52M
AN2 Therapeutics Financials
AN2 Therapeutics reported last fiscal year revenue of — and negative EBITDA of ($38M).
In the same fiscal year, AN2 Therapeutics generated ($38M) in EBITDA losses and had net loss of ($35M).
Revenue (LTM)
AN2 Therapeutics P&L
In the most recent fiscal year, AN2 Therapeutics reported revenue of — and EBITDA of ($38M).
AN2 Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($38M) | XXX | XXX | XXX |
| Net Profit | ($35M) | XXX | ($35M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AN2 Therapeutics Stock Performance
AN2 Therapeutics has current market cap of $110M, and enterprise value of $52M.
Market Cap Evolution
AN2 Therapeutics' stock price is $3.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $110M | -8.8% | XXX | XXX | XXX | $-0.98 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAN2 Therapeutics Valuation Multiples
AN2 Therapeutics trades at (1.4x) EV/EBITDA.
AN2 Therapeutics Financial Valuation Multiples
As of April 11, 2026, AN2 Therapeutics has market cap of $110M and EV of $52M.
Equity research analysts estimate AN2 Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AN2 Therapeutics has a P/E ratio of (3.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV (current) | $52M | XXX | $52M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.4x) | XXX | XXX | XXX |
| P/E | (3.1x) | XXX | (3.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified AN2 Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
AN2 Therapeutics Margins & Growth Rates
AN2 Therapeutics' revenue in the last fiscal year grew by —.
AN2 Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.7M for the same period.
AN2 Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (30%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
AN2 Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Sangamo Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nykode Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| ProMIS Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| PepGen | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AN2 Therapeutics M&A Activity
AN2 Therapeutics acquired XXX companies to date.
Last acquisition by AN2 Therapeutics was on XXXXXXXX, XXXXX. AN2 Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by AN2 Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAN2 Therapeutics Investment Activity
AN2 Therapeutics invested in XXX companies to date.
AN2 Therapeutics made its latest investment on XXXXXXXX, XXXXX. AN2 Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by AN2 Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout AN2 Therapeutics
| When was AN2 Therapeutics founded? | AN2 Therapeutics was founded in 2017. |
| Where is AN2 Therapeutics headquartered? | AN2 Therapeutics is headquartered in United States. |
| How many employees does AN2 Therapeutics have? | As of today, AN2 Therapeutics has over 22 employees. |
| Who is the CEO of AN2 Therapeutics? | AN2 Therapeutics' CEO is Eric Easom. |
| Is AN2 Therapeutics publicly listed? | Yes, AN2 Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of AN2 Therapeutics? | AN2 Therapeutics trades under ANTX ticker. |
| When did AN2 Therapeutics go public? | AN2 Therapeutics went public in 2022. |
| Who are competitors of AN2 Therapeutics? | AN2 Therapeutics main competitors are Zomedica, Sangamo Therapeutics, Nykode Therapeutics, ProMIS Neurosciences. |
| What is the current market cap of AN2 Therapeutics? | AN2 Therapeutics' current market cap is $110M. |
| Is AN2 Therapeutics profitable? | No, AN2 Therapeutics is not profitable. |
| What is the current net income of AN2 Therapeutics? | AN2 Therapeutics' last 12 months net income is ($35M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.